PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frontier BioSciences, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO - Formalized partnership enhances pre-clinical drug development services - FrontierBSI.com
Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO

 

NewswireToday - /newswire/ - Germantown, MD, United States, 2007/03/02 - Formalized partnership enhances pre-clinical drug development services - FrontierBSI.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frontier BioSciences, Inc. today announced that it has signed a formal agreement with the National Chengdu Center for Safety Evaluation of Drugs (NCCSED) to become shareholder and strategic partner in the preclinical contract research service business.

NCCSED was established in 2000 by West China Hospital (WCH) of Sichuan University. Since its inception, this full service preclinical contract research laboratory has become one of the top drug safety evaluation centers in China having received GLP certification by China’s State Food and Drug Administration (SFDA) in 2004. In addition, the NCCSED has been awarded multiple grants from the Ministry of Sciences and Technologies of China. Covering an area of 80,000 sq. ft., this state-of-the-art toxicology facility is comprised of a small SPF animal facility and a conventional large animal facility, equipped with the latest advanced technology and operated by experienced staff with international CRO experience. It has conducted safety and efficacy studies for more than 60 preclinical candidates in the past three years.

“With the NCCSED’s extensive preclinical toxicology experience and unblemished reputation, along with Frontier’s U.S.-trained technical and quality assurance staff, we are poised to provide high-quality and cost-effective services to our customers. We are committed to being a global partner and assisting our customers to move product candidates toward clinic and marketplace”, noted Frontier’s President, Dong Xie, Ph.D.

Additionally, NCCSED’s Director, Li Wang, Ph.D., commented by saying, “With the full technical support of WCH, the largest hospital in Asia with comprehensive teaching and research facility for all medical disciplines, the new partnership will bring online a wide range of preclinical and clinical drug development services, while delivering speed, quality, and economy at international standard. This partnership expands our current capabilities, and displays our commitment to providing top-tier scientific services to customers.”

About Frontier BioSciences, Inc.

Frontier BioSciences, Inc. (frontierbsi.com) is a Maryland-based company providing drug development services for biotechnology and pharmaceutical companies. The company was founded by a team of industry experts, with a strong scientific base in China, as well as extensive CRO experience from the U.S. and Canada. The company has strength in program management, marketing and business development, and international regulatory guidance.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frontier BioSciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Beth Wong - FrontierBSI.com 
301-251-0231 bwong[.]frontierbsi.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frontier BioSciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frontier BioSciences, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)